US equities
|
TSLA
$391.62
▲+5.21%
MU
$903.70
▲+2.98%
META
$630.56
▼-1.88%
NVDA
$216.00
▲+2.39%
AAPL
$343.91
▼-1.10%
SPCX
$146.90
▼-0.40%
MSFT
$532.60
▲+1.54%
AMD
$531.28
▲+2.80%
TSLA
$391.62
▲+5.21%
MU
$903.70
▲+2.98%
META
$630.56
▼-1.88%
NVDA
$216.00
▲+2.39%
AAPL
$343.91
▼-1.10%
SPCX
$146.90
▼-0.40%
MSFT
$532.60
▲+1.54%
AMD
$531.28
▲+2.80%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Articles published by Acumen Pharmaceuticals, Inc.
< Previous
1
2
3
Next >
Acumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Highlights
May 14, 2024
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ABOS
Acumen Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
May 13, 2024
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ABOS
Acumen Pharmaceuticals to Participate in the 2024 Bank of America Healthcare Conference
May 08, 2024
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ABOS
Acumen Pharmaceuticals Announces First Patient Dosed in ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer’s Disease
May 08, 2024
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ABOS
Acumen Pharmaceuticals to Report First Quarter Results on May 14, 2024
May 07, 2024
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ABOS
Acumen Pharmaceuticals Presents First Comprehensive Clinical and Biomarker Data for Sabirnetug (ACU193) at American Academy of Neurology 2024 Annual Meeting
April 16, 2024
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ABOS
Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer’s Disease
April 04, 2024
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ABOS
Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2023 and Business Highlights
March 26, 2024
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ABOS
Acumen Pharmaceuticals to Present Deeper Insights, Including Fluid Biomarker Data for Sabirnetug (ACU193), During Emerging Science Session at the American Academy of Neurology Annual Meeting
March 21, 2024
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ABOS
Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2023 Financial Results on March 26, 2024
March 19, 2024
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ABOS
Acumen Pharmaceuticals to Participate in the Stifel 2024 CNS Days
March 12, 2024
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ABOS
Acumen Pharmaceuticals Presents Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer’s at the AD/PD™ 2024 Annual Meeting
March 08, 2024
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ABOS
Acumen Pharmaceuticals to Present Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer’s at the AD/PD™ 2024 Annual Meeting
February 21, 2024
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ABOS
Acumen Pharmaceuticals Appoints Dr. James Doherty as President and Chief Development Officer
February 01, 2024
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ABOS
Acumen Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 04, 2024
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ABOS
Acumen Pharmaceuticals Reports Third Quarter 2023 Financial Results and Business Highlights
November 13, 2023
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ABOS
Acumen Pharmaceuticals Secures $50.0 Million Credit Facility with K2 HealthVentures
November 13, 2023
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ABOS
Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference
November 07, 2023
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ABOS
Acumen Pharmaceuticals to Report Third Quarter Financial Results on November 13, 2023
November 06, 2023
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ABOS
Acumen Pharmaceuticals, Inc. and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of ACU193 with ENHANZE® Technology
November 06, 2023
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ABOS
Acumen Pharmaceuticals to Participate in the UBS Biopharma Conference
November 02, 2023
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ABOS
Acumen Pharmaceuticals Presents Late-Breaker Phase 1 Updates Exploring Novel Target Engagement, Dosing Regimen and Safety Findings for ACU193 in Early Alzheimer’s Disease at the 16th Annual Clinical Trials on Alzheimer’s Disease
October 27, 2023
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ABOS
Acumen Pharmaceuticals to Present Deeper Insights from First-in-Human Phase 1 Study of ACU193 for Early Alzheimer’s During Symposium at the 16th Annual Clinical Trials on Alzheimer’s Disease (CTAD)
October 04, 2023
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ABOS
Acumen Pharmaceuticals to Participate in the Cantor Global Healthcare Conference
September 19, 2023
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ABOS
Acumen Pharmaceuticals to Participate in the H.C. Wainwright Annual Global Investment Conference
September 06, 2023
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ABOS
Acumen Pharmaceuticals Reports Second Quarter 2023 Financial Results and Business Highlights
August 08, 2023
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ABOS
Acumen Pharmaceuticals to Report Second Quarter Financial Results on August 8, 2023
August 01, 2023
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ABOS
Acumen Announces Pricing of Upsized $130 Million Public Offering
July 18, 2023
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ABOS
Acumen Pharmaceuticals Announces Proposed Public Offering of Common Stock
July 17, 2023
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ABOS
Acumen Pharmaceuticals to Hold Conference Call to Discuss Positive Topline Results from First-in-Human Phase 1 Study of ACU193 for Early Alzheimer’s Disease
July 17, 2023
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ABOS
< Previous
1
2
3
Next >
